Applied Therapeutics (APLT) Net Income towards Common Stockholders (2023 - 2025)
Historic Net Income towards Common Stockholders for Applied Therapeutics (APLT) over the last 3 years, with Q3 2025 value amounting to -$16.6 million.
- Applied Therapeutics' Net Income towards Common Stockholders rose 4147.11% to -$16.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$96.3 million, marking a year-over-year increase of 4328.42%. This contributed to the annual value of -$100.8 million for FY2024, which is 1586.3% up from last year.
- As of Q3 2025, Applied Therapeutics' Net Income towards Common Stockholders stood at -$16.6 million, which was up 4147.11% from -$22.7 million recorded in Q2 2025.
- Applied Therapeutics' 5-year Net Income towards Common Stockholders high stood at -$10.1 million for Q1 2023, and its period low was -$83.9 million during Q1 2024.
- In the last 3 years, Applied Therapeutics' Net Income towards Common Stockholders had a median value of -$28.4 million in 2024 and averaged -$31.7 million.
- In the last 5 years, Applied Therapeutics' Net Income towards Common Stockholders crashed by 72803.59% in 2024 and then soared by 7033.05% in 2025.
- Applied Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$37.7 million in 2023, then increased by 14.91% to -$32.1 million in 2024, then soared by 48.18% to -$16.6 million in 2025.
- Its last three reported values are -$16.6 million in Q3 2025, -$22.7 million for Q2 2025, and -$24.9 million during Q1 2025.